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We congratulate he authors on their meticulous analy- 
sis of all cases reported in the literature. We hope that this 
letter may stimulate further multidisciplinary discussion. 
F. M. Vanhoenacker, MD 
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Reply 
The comments of F. M. Vanhoenacker t al are noted 
with interest. As they correctly point out, there are sever- 
al well-established theories regarding the pathogenesis of
adventitial cystic disease, each with its own protagonists. 
They have summarized some of the evidence in favor of 
the synovial theory and have stressed the significance of 
demonstrating ananatomic ommunication with the rele- 
vant adjacent joint to support heir argument. 
However, histochemistry of the cyst lining has failed to 
demonstrate convincingly a synovial origin for these cells, 
and detailed chemical analysis of adventitial cyst fluid 
demonstrates gross chemical differences of many of the 
fluid constituents when compared with those of synovial 
fluid. 
The correspondents have used as support of the syn- 
ovial theory the age of patients presenting with this enig- 
matic disease, but they fail to mention that this condition 
has been reported in school-aged children. There must 
therefore remain a considerable element of doubt when 
considering the synovial theory. 
In our publication we have drawn attention to the fact 
that all reported adventitial cystic disease occurs in nona~xial 
arteries. This does not constitute proof of the embryological 
theory, but simply lends support o this latter theory. 
It is a dramatic experience to incise an adventitial cyst 
and be treated to the vision of crystal-clear fluid emerging 
from the vessel. The tantalizing macroscopic similarity of 
the adventltial cyst to a simple ganglion and the demon- 
stration of an anatomic ommunication cannot constitute 
absolute proof of the ganglion theory. More definitive 
data about this curious condition are required before this 
argument can be laid to rest. 
Lewis J. Levien, FCS, PhD 
Department ofSurgery 
Milpark Hospital 
Johannesburg, South Africa 
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Regarding "Randomized study of  carotid angioplasty 
and stenting versus carotid endarterectomy: a 
stopped trial" 
To the Editors: 
Naylor and colleagues 1 report the results of a "ran- 
domized study" comparing carotid angioplasty-stenting 
(CAS) and carotid endarterectomy (CEA) in the manage- 
ment of symptomatic extracranial carotid stenosis. These 
investigators andomized 17 patients (10 to CEA and 7 to 
CAS) in a study that presumably was intended to random- 
ize 300 patients but was terminated because of unaccept- 
able results in the CAS group. Although we applaud the 
Leicester group's interest in proceeding with a clinical 
trial, our first observation is their apparent misunder- 
standing of the methodology in selecting a small sample 
size of only 300 patients, which we regard as inadequate 
to answer this question. The CREST (Carotid Revascu- 
latization Endarterectomy vs Stent Trial) investigators, 2 
recently funded by a grant from the National Institute for 
Neurological Disorders and Stroke, National Institutes of 
Health, have planned for a sample size of 2500 sympto- 
matic patients to determine clinical efficacy for these two 
procedures. Furthermore, the safety considerations insti- 
tuted by Naylor and colleagues were unacceptable in our 
opinion. We seek to reassure clinicians in North America 
and Europe who have xpressed interest in participation i
CREST that no matter how sldlled an interventionalist 
might be in the peripheral or coronary circulations, ran- 
domization of cases will not proceed until the interven- 
tionalist has attended a Carotid Stent Operators' 
Certification Program and has performed required preran- 
domization run-in procedures. Results will be reviewed by 
the Interventional Management Committee using prede- 
fined established criteria before randomization ofcases can 
be initiated. During the performance of these cases or sub- 
sequently during the trial, one major complication (stroke 
or death) wilt result in a "watch status" for the institution, 
and a second major complication requires a site visit from 
the Surgical Management Committee, if it occurs with 
CEA, or from the Interventional Management Corn- 
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mittee, if it occurs with CAS. This provides a level of safe- 
ty, which is similar to that adopted by prior randomized 
clinical trials evaluating the efficacy of CEA verus medical 
management), 4 Had Naylor and colleagues adopted sim- 
ilar safeguards, the occurrence of five strokes in seven 
interventional procedures, which limited and in fact 
"stopped" the trial, could have been avoided. Publication 
of their report serves only to undermine the importance of 
randomized clinical trial methodology, which is the only 
mechanism whereby Level I or II evidence will be derived. 
A preferred title for their manuscript might have been 
"Randomized study of carotid angioplasty and stenting 
versus carotid endarterectomy: a trial that never should 
have been started." 
As we approach a position of clinical equipoise s on 
these two alternatives in the management of symptomatic 
extracranial carotid occlusive disease, we wish to reassure 
the vascular surgical community about the safety precau- 
tions adopted by CREST. A well-designed clinical trial 
with appropriate safeguards will provide an efficacy assess- 
ment of these two procedures before clinicians consider 
expanded use of CAS. 
Robert W. Hobson II, MD, 
for the Executive Committee, CREST 
UMDNJ-New Jersey Medical School 
Newark, NJ 
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Reply 
We thank Dr Hobson for his letter regarding the 
Leicester Carotid Angioplasty Trial) Its somewhat per- 
sonal style and belated submission (14 months after pub- 
lication) suggest hat it has been motivated by an under- 
standable desire to publicize CREST at a time of concern 
about the clinical equipoise, performance, and interpreta- 
tion of randomized trials of endarterectomy versus angio- 
plasty. We are,.however, pleased to respond regarding the 
safety and generalizability of randomized trials. 
Dr Hobson states that the safety considerations in our 
trial were "unacceptable" and impfies that the intervention- 
ist had not received appropriate raining. The latter criticism 
is quite unfounded. In addition to visiting one of the 
aclmowledged experts on carotid stenting (Dr Mathias in 
Germany), Dr Bolia performed a series ofangioplasfies with- 
out complication before patients were randomized. At the 
time, there was no certification program anywhere in the 
world, and Dr Bolia's results exactly paralleled the excelent 
results reported in the 1992 overview of angioplasty out- 
comes) When all symptomatic patients were later random- 
ized within the trial, complications did occur. However, 
when the videos were critically reviewed, we were unable to 
identify any specific problem with technique. 
As in the forthcoming CREST study, the Leicester 
trial did incorporate "we-defined criteria" before random- 
ization was considered and had specified stopping rules 
according to established statistical methods that were 
overseen by an independent Data Monitoring Committee. 
We do, however, agree that the question of balancing safe- 
ty against compromising the statistical integrity of interim 
analyses is particularly difficult, especially in the era of 
individual versus collective ethics. Dr Hobson's letter 
implies an understandable move toward individual ethics 
(ie, the needs of the individual outweigh the needs of the 
many), but it remains an inescapable fact that multicenter 
randomized trials rely on collective thics to provide infor- 
mation that will truly predict overall clinical practice. This 
problem was specifically raised in the discussion section of 
our paper. 
All randomized trials undertake interim analyses, so 
that the Data Monitoring Committee can assess afety and 
efficacy. However, interim analyses increase the likelihood 
of a type I error, 3whereby "chance" rather than technique 
may be responsible for adverse vents. Accordingly, the 
group sequential method with a predetermined level of 
significance was used to balance the important issues of 
individual safety and chance in the performance of the 
study. Ironically, it remains the opinion of some that our 
trial was suspended prematurely with the results simply 
reflecting the effect of chance. While not having seen the 
CREST protocol, Dr Hobson seems to imply that 2+ 
adverse vents (within how many cases?) could lead to sus- 
pension of that investigator f om recruitment, despite the 
investigator's having fulfilled the criteria to participate. 
Alternatively, the prospect of the investigator receiving a
visit from the trial regulators will inevitably alter his or her 
clinical equipoise for future trial recruitment. I f this is 
true, there is the very real risk of introducing significant 
bias, thereby compromising statistical integrity and the 
generalizability of any results. Clearly there is no easy solu- 
tion to reconciling this most difficult of ethical problems. 
We consider the comment that our trial "should never 
have been started" smacks of shooting the messenger 
while not listening to the message. Generalizability still 
remains a problem for endarterectomy because outcomes 
are currently not as good as those in the international tri- 
als. 4 This could also be a problem for angioplasty. At pre- 
